Description

Newly Approved and Late-Stage Investigational Treatments for Castration-Resistant Prostate Cancer: Mechanism of Action and Efficacy 

Participate in this innovative online activity to find a thorough review of the latest clinical trial data and treatment guidelines for castration-resistant prostate cancer, as well as guidance on the mechanism of action and efficacy of newly approved and late-stage investigational treatments.

It's critical for oncology clinicians to stay current with evolving standards of care for patients with prostate cancer, as well as participate in education that mirrors the dynamics of real-life clinical decision making. This activity not only reviews the latest data and treatment options for castration-resistant prostate cancer, but also provides an enhanced understanding of adverse effects and helps optimize patient selection for new therapies recently approved and in late-stage clinical trials. Led by experts from the Massachusetts General Hospital Cancer Center, the content of the activity follows a Script Concordance Test (SCT) structure that presents a description of a clinical case followed by a treatment option such as palliative care, then subsequently adds new information such as the patient asking if any therapy can prolong life. As an oncology clinician, you must decide if the new information makes the original treatment option more or less appropriate, and explain your clinical decisions.

To receive credit for this two-hour interactive Computer Simulation Assessment Tool (CSAT), you must view the activity and complete the activity evaluation. 

Learning Objectives

  • Discuss new therapeutic approaches to prostate cancer.
  • Describe mechanisms of action and efficacy of newly approved and late-stage investigational treatments for castration-resistant prostate cancer.
  • Outline adverse effects and patient selection for new therapies recently approved and in late-stage clinical trials for castrate-resistant prostate cancer.  

Target Audience

Community oncologists, oncology nurses, and other health care professionals involved in the care and treatment of those affected with castration-resistant prostate cancer.

Faculty

Supporters

This activity has received support in the form of an educational grant from the following companies: Bayer Healthcare Pharmaceuticals, Inc. and Astellas Scientific and Medical Affairs, Inc.

Agenda

Part 1 (CSAT Activity): Participate in the interactive script concordance activity (60 minutes)

Part 2 (Resource Library): Review supplemental readings (60 minutes)

CME Information

Release Date: February 28, 2014
Expiration Date: February 28, 2015

To receive credit for this two-hour interactive activity, participate in the interactive script concordance activity (60minutes), review additional readings (60 min), and complete the activity evaluation.

Accreditation Statement

Partners HealthCare System is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Partners HealthCare System designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Professions: This course allows other providers to claim a Participation Certificate upon successful completion of this course. Participation Certificates will specify the title, location, type of activity, date of activity, and number of AMA PRA Category 1 Credits™ associated with the activity. Providers should check with their regulatory agencies to determine ways in which AMA PRA Category 1 Credits™ may or may not fulfill continuing education requirements. Providers should also consider saving copies of brochures, agenda, and other supporting documents.


Faculty Disclosure Statement

In accord with the disclosure policy of Partners HealthCare System as well as guidelines of the Accreditation Council for Continuing Medical Education (ACCME), planners and speakers have been asked to disclose any relationship they have to companies producing pharmaceuticals, medical equipment, devices, etc. that may be germane to the content of their presentation. Such disclosure is not intended to suggest or condone bias, but provides participants with information that might be of potential importance to their evaluation of a given presentation.

Resolution of Conflicts of Interest (COI)

Partners HealthCare System has implemented a process to resolve potential COIs for this CME activity to help ensure content objectivity, independence, fair balance and ensure that the content is aligned with the interest of the public.  


Planner Disclosures

The following planners and/or their spouse/partner have reported no relevant financial relationship with a commercial interest:

M. Dror Michaelson, MD, PhD, Reviewer

Tristan Gorrindo, MD

Jane Pimental, MPH

The following planners and/or their spouse/partner have reported a relevant financial relationship with a commercial interest:

Robert Birnbaum, MD, PhD

Honorarium/Panel Discussant: Advanstar Communications Inc.

Honorarium/Plenary Panel: ACEHP

Royalty/Editor: UpToDate 


Speaker Disclosures

The following speaker and/or his spouse/partner have reported no relevant financial relationships with a commercial interest:

M. Dror Michaelson, MD, PhD, Reviewer

Mark Pomerantz, MD

Philip J. Saylor, MD

Mary Ellen Taplin, MD

The following speakers and/or their spouse/partner have reported a relevant financial relationship with a commercial interest:

Robert Dreicer, MD, MS, FACP

Honorarium/Advisory Board: Janssen, Millennium, Medivation

Jorge J. Garcia, MD

Honorarium/Advisory Board: Astellas, Bayer

Honorarium/Advisory Board, Speaker: Johnson & Johnson

Richard J. Lee, MD, PhD

Honorarium/Speaker: Medivation, Janssen

William K. Oh, MD

Honorarium/Speaker: Astellas, Bayer, Dendreon, Janssen, Medivation, Sanofi-Aventis

Oliver Sartor, MD

Consultant: Algeta, Aragon, Astellas, Bavarian-Nordic, Bayer, Bellicum, Dendreon, Johnson & Johnson, Medivation, Oncogenex, Pfizer, Sanofi-Aventis

Grant and Research Support: Algeta, Bayer, Johnson & Johnson, Sanofi-Aventis, Takeda   

Matthew R. Smith, MD, PhD

Consulting fees: Amgen, Astellas, Bayer, Janssen

Christopher Sweeney, MD

Honorarium/Consultant: Astellas, BIND, Bionomics, Genentech, Janssen

Evan Y. Yu, MD

Honorarium/Advisory Board: Amgen, Astellas, Bayer, Dendreon, Janssen, Medivation

 


Supporters

This activity has received support in the form of an educational grant from the following companies: Bayer Healthcare Pharmaceuticals, Inc. and Astellas Scientific and Medical Affairs, Inc.

 


Hardware/Software Specifications:
This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.

Optimal System Configuration:
Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher

Minimum Requirements:
Windows PC:
500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Macintosh:
Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit


Privacy Policy:
Please click here to review our privacy policy.